HomeNewscoronavirusCoronavirus outbreak | US researchers identify small molecules that can block COVID-19

Coronavirus outbreak | US researchers identify small molecules that can block COVID-19

The research scientist noted that the SARS-CoV-2 protein PLpro is essential for the replication and the ability of the virus to suppress host immune function.

June 13, 2020 / 21:12 IST

The team of researchers at the University of Georgia (UGA) in the US have identified that a set of small molecules that can block the activity of a key protein in SARS-CoV-2 that causes COVID-19, a finding that provides a promising path for new therapeutics for the disease.

The research scientist noted that the SARS-CoV-2 protein PLpro is essential for the replication and the ability of the virus to suppress host immune function. The compounds, naphthalene-based PLpro inhibitors, are shown to be effective at halting SARS-CoV-2 PLpro activity as well as replication, according to the research published in the journal ACS Infectious Diseases.

The researchers explored inhibitors designed to knock out PLpro and stop the replication of the virus. They began with a series of compounds that were discovered 12 years ago and shown to be effective against SARS, but development was cut short since SARS had not reappeared.

"Obviously now we see the current coronavirus is probably going to be with us for a while -- if not this one, then probably other types of coronaviruses," said Scott Pegan, a professor at UGA.

"These compounds are a good starting point for therapeutic development. They have all the properties you would typically want to find in a drug, and they have a history of not being considered toxic," he said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The compounds offer a potential rapid development path to generating PLpro-targeted therapeutics for use against SARS-CoV-2, the researchers said. The kind of small molecules that we're developing are some of the first that are specifically designed for this coronavirus protease," Pegan said.

"Up till now, most therapeutic work against SARS has targeted another virulence factor, C3Lpro. This is a great start with a different target. Our hope is that we can turn this into a starting point for creating a drug that we can get in front of the Food and Drug Administration," he said.

Follow our full coverage of the coronavirus pandemic here.

PTI
first published: Jun 13, 2020 09:12 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347